Cargando…

Erythropoietin and a hypoxia‐inducible factor prolyl hydroxylase inhibitor (HIF‐PHDi) lowers FGF23 in a model of chronic kidney disease (CKD)

Iron‐deficiency anemia is a potent stimulator of the phosphaturic hormone Fibroblast growth factor‐23 (FGF23). Anemia, elevated FGF23, and elevated serum phosphate are significant mortality risk factors for patients with chronic kidney disease (CKD). However, the contribution of anemia to overall ci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Noonan, Megan L., Clinkenbeard, Erica L., Ni, Pu, Swallow, Elizabeth A., Tippen, Samantha P., Agoro, Rafiou, Allen, Matthew R., White, Kenneth E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261757/ https://www.ncbi.nlm.nih.gov/pubmed/32476270 http://dx.doi.org/10.14814/phy2.14434

Ejemplares similares

Segregating the effects of ferric citrate‐mediated iron utilization and FGF23 in a mouse model of CKD
por: Liesen, Michael P., et al.
Publicado: (2022)

SUN-351 Sex Is a Strong Variable in the Mineral Metabolism Defects and Endocrine Dysfunction Associated with the Murine Adenine Diet Model of Chronic Kidney Disease (CKD)
por: Liesen, Michael P, et al.
Publicado: (2020)

Osteocytic FGF23 and Its Kidney Function
por: Agoro, Rafiou, et al.
Publicado: (2020)

Neuroprotective Effect of HIF Prolyl Hydroxylase Inhibition in an In Vitro Hypoxia Model
por: Savyuk, Maria, et al.
Publicado: (2020)

Tuning the Transcriptional Response to Hypoxia by Inhibiting Hypoxia-inducible Factor (HIF) Prolyl and Asparaginyl Hydroxylases
por: Chan, Mun Chiang, et al.
Publicado: (2016)

The role of HIF prolyl hydroxylases in tumour growth
por: Jokilehto, Terhi, et al.
Publicado: (2010)

Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitors for the Treatment of Anemia in CKD: Additional Pieces of the Jigsaw Puzzle
por: Wish, Jay B.
Publicado: (2021)

The anaemia treatment journey of CKD patients: from epoetins to hypoxia-inducible factor-prolyl hydroxylase inhibitors
por: Locatelli, Francesco, et al.
Publicado: (2023)

Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state
por: Joharapurkar, Amit A., et al.
Publicado: (2022)

Osteocyte Egln1/Phd2 links oxygen sensing and biomineralization via FGF23
por: Noonan, Megan L., et al.
Publicado: (2023)

Minoxidil Induction of VEGF Is Mediated by Inhibition of HIF-Prolyl Hydroxylase
por: Yum, Soohwan, et al.
Publicado: (2017)

Microbiota-derived butyrate is an endogenous HIF prolyl hydroxylase inhibitor
por: Wang, Ruth X., et al.
Publicado: (2021)

Inhibition of HIF-prolyl hydroxylases improves healing of intestinal anastomoses
por: Strowitzki, Moritz J., et al.
Publicado: (2021)

Role of prolyl hydroxylase/HIF-1 signaling in vascular calcification
por: Negri, Armando Luis
Publicado: (2022)

HIF-independent role of prolyl hydroxylases in the cellular response to amino acids
por: Durán, R V, et al.
Publicado: (2013)

FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase
por: Flamme, Ingo, et al.
Publicado: (2017)

Inactivation of HIF‐prolyl 4‐hydroxylases 1, 2 and 3 in NG2‐expressing cells induces HIF2‐mediated neurovascular expansion independent of erythropoietin
por: Urrutia, Andrés A., et al.
Publicado: (2020)

Lack of activity of recombinant HIF prolyl hydroxylases (PHDs) on reported non-HIF substrates
por: Cockman, Matthew E, et al.
Publicado: (2019)

miR-190 Enhances HIF-Dependent Responses to Hypoxia in Drosophila by Inhibiting the Prolyl-4-hydroxylase Fatiga
por: De Lella Ezcurra, Ana Laura, et al.
Publicado: (2016)

Structural basis for oxygen degradation domain selectivity of the HIF prolyl hydroxylases
por: Chowdhury, Rasheduzzaman, et al.
Publicado: (2016)

Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials
por: Yeh, Tzu-Lan, et al.
Publicado: (2017)

HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons
por: Poloznikov, Andrey A., et al.
Publicado: (2021)

Precisely Tuned Inhibition of HIF Prolyl Hydroxylases Is Key for Cardioprotection After Ischemia
por: Jatho, Aline, et al.
Publicado: (2021)

A Novel Choice to Correct Inflammation-Induced Anemia in CKD: Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat
por: Yan, Zhipeng, et al.
Publicado: (2020)

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors and Iron Metabolism
por: Ogawa, Chie, et al.
Publicado: (2023)

Hypoxia inducible factor prolyl hydroxylases in inflammatory bowel disease
por: Lun, Jie, et al.
Publicado: (2023)

HIF-α Prolyl Hydroxylase Inhibitors and Their Implications for Biomedicine: A Comprehensive Review
por: Hirota, Kiichi
Publicado: (2021)

The HIF-prolyl hydroxylases have distinct and nonredundant roles in colitis-associated cancer
por: Kennel, Kilian B., et al.
Publicado: (2022)

Novel Dioxygenases, HIF-α Specific Prolyl-hydroxylase and Asparanginyl-hydroxylase: O(2) Switch for Cell Survival
por: Park, Hyunsung
Publicado: (2008)

Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors induce autophagy and have a protective effect in an in-vitro ischaemia model
por: Singh, Ayesha, et al.
Publicado: (2020)

Expression and Roles of Individual HIF Prolyl 4-Hydroxylase Isoenzymes in the Regulation of the Hypoxia Response Pathway along the Murine Gastrointestinal Epithelium
por: Dengler, Franziska, et al.
Publicado: (2021)

C-FGF23 peptide alleviates hypoferremia during acute inflammation
por: Agoro, Rafiou, et al.
Publicado: (2020)

Collagen prolyl 4-hydroxylase 1 is essential for HIF-1α stabilization and TNBC chemoresistance
por: Xiong, Gaofeng, et al.
Publicado: (2018)

Hypoxia-inducible factor prolyl hydroxylase inhibitors in kidney transplant recipients
por: Ogata, Masatomo, et al.
Publicado: (2022)

Bibliometric analysis of hypoxia inducible factor prolyl hydroxylase inhibitor in anemia
por: Zheng, Li, et al.
Publicado: (2022)

Gas tunnel engineering of prolyl hydroxylase reprograms hypoxia signaling in cells
por: Windsor, Peter, et al.
Publicado: (2023)

Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors
por: Locatelli, Francesco, et al.
Publicado: (2022)

No benefit of HIF prolyl hydroxylase inhibition for hypertensive renal damage in renovascular hypertensive rats
por: Hartner, Andrea, et al.
Publicado: (2023)

An Overview of Safety and Efficacy Between Hypoxia-Inducible Factor-Prolyl-Hydroxylase Inhibitors and Erythropoietin-Stimulating Agents in Treating Anemia in Chronic Kidney Disease Patients
por: Sonia, Shamsun Nahar, et al.
Publicado: (2023)

Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia
por: Li, Jing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tpdolboon6h18i1g7aq9e6m91e